Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symlin vs rapid-acting insulin intensification in type 2 diabetes
NCT00467649Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2007
- Primary completion
- Apr 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of pramlintide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2007; status: completed.
02
Drugs
pramlintide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00467649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467649.